Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Novo Nordisk has filed another Citizen's Petition ... The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Nina Kritzberger, 16, speaks before the Government and Veteran Affairs Committee in favor of an insulin cap for the North ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Novo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal to buy US biotech Corvidia Therapeutics and its lead drug for chronic kidney disease ...